Two new studies testify that individuals taking medications containing the substance Semaglutid – which is found in the popular diabetes medication Ozempic, among other things – run an increased risk of developing the eye disease Naion.
The European Medicines Agency's safety committee PRAC has therefore initiated a review of medications like Ozempic, writes the Medical Products Agency on its website.
Naion is a disease caused by reduced blood flow to the optic nerve in the eye, which can lead to vision loss.
Medications containing the substance Semaglutid are approved for the treatment of type 2 diabetes and for the treatment of overweight in certain cases. Diabetes patients may already have an increased risk of developing Naion.
According to the Medical Products Agency, however, there are also studies that show that there is no increased risk of Naion when taking Semaglutid.
